Gavín Sebastián Olga, Izuzquiza Fernández Macarena, Martínez Fernández Raquel, Palomera Bernal Luis
Servicio de Hematología y Hemoterapia, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Future Cardiol. 2018 May;14(3s):25-30. doi: 10.2217/fca-2018-0023.
To assess the clinical profile and thromboembolic and bleeding events in patients with nonvalvular atrial fibrillation (AF) who were attended in a hematology unit.
Retrospective study of AF patients that started treatment with rivaroxaban between February 2012 and June 2016 in a hematology unit from a tertiary hospital in Spain.
Overall, 243 patients (mean age 78.4 ± 10.1 years; 47.5% women, CHADS-VASc 3.7 ± 1.5) were included. After a mean follow-up of 16.5 ± 12.7 months, rivaroxaban was discontinued in only 2.4% of patients. During the follow-up, seven (2.0 events/100 patient-years) patients had a thromboembolic event and six patients (1.7 events/100 patient-years) a major bleeding.
Rivaroxaban was effective and safe among AF patients treated in a hematology unit, with very low discontinuation rates.
评估在血液科就诊的非瓣膜性心房颤动（AF）患者的临床特征、血栓栓塞事件和出血事件。
对2012年2月至2016年6月期间在西班牙一家三级医院血液科开始使用利伐沙班治疗的AF患者进行回顾性研究。
共纳入243例患者（平均年龄78.4±10.1岁；47.5%为女性，CHADS-VASc评分为3.7±1.5）。平均随访16.5±12.7个月后，仅2.4%的患者停用利伐沙班。随访期间，7例患者（2.0次事件/100患者年）发生血栓栓塞事件，6例患者（1.7次事件/100患者年）发生大出血。
在血液科接受治疗的AF患者中，利伐沙班有效且安全，停药率极低。
